Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. - Wikidata - awgldk - TriplyDB

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

http://www.wikidata.org/entity/Q33358579

about

Malignant gliomas: old and new systemic treatment approaches Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas Medical management of brain tumors and the sequelae of treatment.Temozolomide: a milestone in neuro-oncology and beyond?The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.IFN-conditioned dendritic cells for the therapy of melanoma: what is missing?A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response.The anti-angiogenic basis of metronomic chemotherapy.Canadian recommendations for the treatment of glioblastoma multiforme.Immunotherapy for human glioma: innovative approaches and recent results.Combining cancer vaccines with chemotherapy.Impact of temozolomide on immune response during malignant glioma chemotherapy Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas.Temozolomide: a milestone in the pharmacotherapy of brain tumors.Metronomic dosing of chemotherapy: applications in pediatric oncology.Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas.Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.Chemotherapy in the management of advanced cutaneous malignant melanoma.Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model Aspergillosis in a patient receiving temozolomide for the treatment of glioblastoma.

P2860

Q26744387-A65DFC2C-5EEB-49BC-832F-8E9774114229 Q26765459-0ADF5B3F-94B5-4E59-ACE3-661BB9EAF4B5 Q26862551-5237F92B-7750-462F-A2FD-5E7D8FE79086 Q26992174-1E781BC8-F508-4C6F-97B1-59185B00574E Q33372340-870A5588-1D3B-406F-8FE5-EE9841B2499B Q33373291-16EE8BD3-7267-464F-8E06-3F1A6F8CD626 Q33391731-55F28138-412F-4FD0-BE84-BA2B3B95E6DD Q33633272-27AF701D-076E-4FCC-BDAE-4BA53AC4DEDA Q34186787-71117CC0-7E31-4023-98DD-7740440C738A Q34316147-9ECD96FC-852C-4164-8FB7-F46332DCAA17 Q34480557-63B488E3-9FA6-4E99-B158-11BBFE91CE9D Q34634616-F9E71363-5B3F-4105-99AC-13CFF52B44B7 Q34722415-9E4BF944-3CC7-4D9E-9BBE-F494D5ED5A53 Q34722857-B0CA7930-604A-42E1-9A85-41CCD26B93FB Q34775318-66612D44-3C9F-4542-B3B6-091B19B9F710 Q34992535-B472F0E5-306C-473B-8082-CA03BDE3FE70 Q35162266-AD2D4B76-44E6-40F0-931F-042B67E26292 Q35167257-9D3A575C-31B5-4B2F-8BDB-AC474E3FFFD9 Q35196720-FFB971DB-A102-4358-A808-1175ED99DC8E Q35220386-D5958521-BCAB-4521-89BC-1976B74D451C Q35250795-E0E19AD3-BDD6-4FE9-8359-FFBC5076FAD7 Q35602183-464D548E-419C-43A7-8A67-DB789BE7223F Q35788112-2D657D41-D522-42D2-AD8A-7236CB90AB3E Q35855352-DE02A740-115C-4485-B2C6-CD1928B6DE38 Q36284489-863A5D3B-2F71-4490-A0EB-608E72E3C8CF Q36327092-547E6744-8FD6-4D67-A320-F6545CB69DC9 Q36362798-DD39E775-7C23-47AA-9E4B-F10DD7F758F4 Q36416343-7B9FFCEE-6E43-49C0-87C9-72E42CB9E07E Q36429611-92846EAE-34C5-41B4-AD3C-80EB4D66466C Q36508092-5BFA7B2F-10D0-46E7-A9A4-44A2575F7356 Q36558234-31D707F6-F3D8-4318-8DE9-530EC198384E Q36569129-5F6748B0-289B-49C8-AC72-B5EBB4701084 Q36611825-85117E24-F4A1-412F-9F7E-C56E164194A5 Q36694942-47D04DF3-2490-4CF5-8FC9-2B99660A53AB Q36968570-4A564474-B39C-4831-B798-2A82048B93D7 Q36972613-1351BB9F-6CDA-49C0-A8D3-8311C7680B4B Q37007984-6A8CB55E-2A7D-4264-B21A-DF0D986CDA76 Q37011021-53CC774C-62E9-445C-9856-6FA5D1984A61 Q37148914-F22591C5-376C-4F29-8900-E46E5C437448 Q37151373-03258957-6ACA-4C3B-ADC5-3A0CE39581B9

P2860

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

http://www.wikidata.org/entity/Q33358579

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

Selective CD4+ lymphopenia in ...... with therapeutic implications.

@ast

Selective CD4+ lymphopenia in ...... with therapeutic implications.

@en

type

label

Selective CD4+ lymphopenia in ...... with therapeutic implications.

@ast

Selective CD4+ lymphopenia in ...... with therapeutic implications.

@en

prefLabel

Selective CD4+ lymphopenia in ...... with therapeutic implications.

@ast

Selective CD4+ lymphopenia in ...... with therapeutic implications.

@en

P1433

Q33358579-6605AA47-F3A4-4800-A7A9-5327851D59F5

P1476

Q33358579-5BCE9AEB-56C9-41E2-974B-B112DE3CACF9

P2093

Q33358579-0C91287E-C02D-4E1F-A486-87D17A66A130

Q33358579-1E0AC260-2AE8-4AB1-9BC1-5D803BEDC1F8

Q33358579-20A5925A-4C62-41C4-ACE9-8128282D35CF

Q33358579-33518796-3075-4B18-8735-DEECA369ED80

Q33358579-511C2EA8-905E-4079-A0F5-CECBE68E1025

Q33358579-5974DC69-0AD2-43E4-B151-9E0BC0BB8BF6

Q33358579-703784AA-9004-4DED-9099-44C0FB11117C

Q33358579-81CF646F-D1FD-4E62-AD78-B632868A5867

Q33358579-B349D14F-1CDA-45B6-8676-B9624D5A94EA

Q33358579-CCF699EE-F0C6-4678-BA2A-9E81310514C3

P304

Q33358579-B6813044-9109-4491-A284-340CB2980F58

P31

Q33358579-482AF3A2-A329-4FDB-BA69-978817610578

P356

Q33358579-AEE1C3D3-0DA2-410A-9BD1-9220FFC3B635

P407

Q33358579-A5F5D459-944D-4259-B09F-59AC22DE2810

P433

Q33358579-C80E6AE4-82CB-46BC-A8B7-BA7DD393AF41

P478

Q33358579-0A38D3B2-BF47-4E8B-BBA1-CC132ED97152

P577

Q33358579-675ED670-C4B4-45CE-9838-1F126A092990

P698

Q33358579-5A98F2C9-41A4-45E9-8366-3FA117F1C24A

P356

JCO.2004.07.060

P1433

Journal of Clinical Oncology

P1476

Selective CD4+ lymphopenia in ...... with therapeutic implications.

@en

P2093

Carolyn Quinn

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Kent A Sepkowitz

http://www.w3.org/2001/XMLSchema#string

Linda Williams

http://www.w3.org/2001/XMLSchema#string

Paul B Chapman

http://www.w3.org/2001/XMLSchema#string

Philip O Livingston

http://www.w3.org/2001/XMLSchema#string

Sejean Sohn

http://www.w3.org/2001/XMLSchema#string

Susan E Krown

http://www.w3.org/2001/XMLSchema#string

Theresa Foster

http://www.w3.org/2001/XMLSchema#string

Y B Su

http://www.w3.org/2001/XMLSchema#string

P304

610-616

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.07.060

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14726505

http://www.w3.org/2001/XMLSchema#string